Skip to main content
SpringerLink
Log in

Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background We aimed to comprehensively evaluate the prognostic value of inflammation-based prognostic scores, including the modified Glasgow Prognostic Score (mGPS), neutrophil–lymphocyte ratio (NLR), and platelet–lymphocyte ratio (PLR), exclusively in patients with advanced intrahepatic cholangiocarcinoma (iCCA). Methods Between May 2010 and April 2015, 305 patients with histologically documented unresectable or metastatic iCCA were treated with first-line gemcitabine plus cisplatin (GemCis). Among these, 257 patients had complete data for inflammation-based prognostic scores and were included. Results Median age was 59 (range: 27–78) years, and 158 patients (61.5%) were males. High mGPS was independently associated with poor progression-free survival (PFS; mGPS ≥1 vs. 0: median, 3.9 vs. 5.5 months; P = 0.001) and overall survival (OS; mGPS ≥1 vs. 0; median, 6.9 vs. 14.1 months; P = 0.002) in the multivariate analysis. Regarding high NLR (> median) and PLR (> median), although a potential association existed with poor PFS or OS in the univariate analysis, these did not remain as significant in the multivariate analyses. Conclusion The current study suggests that mGPS might be the relevant prognostic index that could stratify the survival outcomes of patients with unresectable or metastatic iCCA who received first-line GemCis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243

    Article  PubMed  Google Scholar 

  2. Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289

    Article  PubMed  Google Scholar 

  3. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281

    Article  CAS  PubMed  Google Scholar 

  4. Bridgewater J, Lopes A, Wasan H et al (2015) Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 27:134–140

    Article  PubMed  Google Scholar 

  5. Kim BJ, Yoo C, Kim KP et al (2017) Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 116:561–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee SY, Kim HS, Choi YJ et al (2016) A Prognostic Index to Identify patients with intrahepatic cholangiocarcinoma who could benefit from gemcitabine plus cisplatin. Am J Ther 23:e1449–e1455

    Article  PubMed  Google Scholar 

  7. Zhang C, Wang H, Ning Z et al (2016) Prognostic nutritional index serves as a predicative marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma. Onco Targets Ther 9:6417–6423

    Article  PubMed  PubMed Central  Google Scholar 

  8. McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 39:534–540

    Article  PubMed  Google Scholar 

  9. Lin G, Liu Y, Li S et al (2016) Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma. Oncotarget 7(32):50963–50971

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kawakita D, Tada Y, Imanishi Y et al (2017) Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan. Oncotarget 8:1083–1091

    Article  PubMed  Google Scholar 

  11. Ha H, Nam AR, Bang JH et al (2016) Soluble programmed death-ligand 1 (sPDL1) and neutrophil- to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget 7(47):76604–76612

    Article  PubMed  PubMed Central  Google Scholar 

  12. Goh BK, Chok AY, Allen JC Jr et al (2016) Oncology/Genetics Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors. Surgery 159:1146–1156

    Article  PubMed  Google Scholar 

  13. Kim BJ, Hyung J, Yoo C et al (2017) Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 80(1):209–215

    Article  CAS  PubMed  Google Scholar 

  14. Chen Q, Dai Z, Yin D et al (2015) Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma. Medicine (Baltimore) 94(13):e574

    Article  CAS  Google Scholar 

  15. Pan QX, Su ZJ, Zhang JH et al (2017) Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma. Mol Clin Oncol 6(4):566–574

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cho KM, Park H, Oh DY et al (2017) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget 8(2):2329–2341

    PubMed  Google Scholar 

  17. Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010

    Article  CAS  PubMed  Google Scholar 

  18. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  20. Deng M, Ma X, Liang X et al (2017) Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 8(23):37200–37207

    Article  PubMed  PubMed Central  Google Scholar 

  21. Li X, Chen ZH, Xing YF et al (2014) Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol 36(4):2263–2269

    Article  CAS  PubMed  Google Scholar 

  22. Chan SL, Chan AWH, Chan AKC et al (2016) Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int 37:280–289

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Bio and Medical Technology Development Program of the NRF funded by the Korean government, MSIP (NRF-2016M3A9E8941331) and a grant from the Asan Institute for Life Sciences at Asan Medical Center in Seoul, Korea (2017-752).

Author information

Author notes

  1. Changhoon Yoo and Baek-Yeol Ryoo contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea

    Hyungwoo Cho, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Jihoon Kang, Heung-Moon Chang & Baek-Yeol Ryoo

  2. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea

    Sang Soo Lee, Do Hyun Park, Tae Jun Song, Sung Koo Lee, Myung-Hwan Kim, Han Chu Lee, Young-Suk Lim, Kang Mo Kim & Ju Hyun Shim

  3. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea

    Shin Hwang, Gi-Won Song, Deok-Bog Moon, Jae Hoon Lee & Young-Joo Lee

Authors
  1. Hyungwoo Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changhoon Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyu-pyo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Ho Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jihoon Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heung-Moon Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sang Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Do Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tae Jun Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sung Koo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Myung-Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Han Chu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Young-Suk Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kang Mo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ju Hyun Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shin Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Gi-Won Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Deok-Bog Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Jae Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Young-Joo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Baek-Yeol Ryoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Changhoon Yoo or Baek-Yeol Ryoo.

Ethics declarations

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Ethical approval

This study was approved by the Institutional Review Board at the Asan Medical Center.

Informed consent

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, H., Yoo, C., Kim, Kp. et al. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 36, 496–502 (2018). https://doi.org/10.1007/s10637-017-0548-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-017-0548-7

Keywords

Search

Navigation